Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Dysfunction of natural koller cells (NK cells) is an important factor in the development of endometriosis. NK cell therapy was applied to treat severe endometriosis, which is an exploration of the pathogenesis of this refractory disease.
Endometriosis (EMs) is one of the common and frequently occurring diseases in women of childbearing age, which seriously affects the health and quality of life of the vast majority of women. The pathogenesis of endometriosis is unknown until now, and the recurrence rate of existing treatment methods is high. It is more and more necessary to introduce new therapeutic methods and strategies in view of the mechanism associated with the reduction of natural killer cell (NK) cytotoxicity. In this study, routine therapy combined with NK cell therapy was used in the treatment of severe endometriosis. The clinical data were collected to confirm the efficacy and safety of NK cell therapy. It is expected to provide a new way of thinking and method for the clinical treatment of EMs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conventional treatment group | Other | GnRHa combained with reverse addition therapy |
|
| Conventional treatment and Autologous NK cells therapy | Experimental | GnRHa combained with reverse addition therapy and NK cell combined treatment group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Autologous NK cell therapy | Biological | After conventional treatment, the patients were treated with autologous NK cells. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety] | Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 | 3 months after treatment |
| Purity and Function of NK cells | The purity and function of NK cells will be measured by flow cytometry. | once per three months |
| Measure | Description | Time Frame |
|---|---|---|
| Endocrine hormone levels | The levels of endocrine hormone, including serum estradiol, testosterone, progesterone, luteinizing hormone and follicle stimulating hormone will be measured. | every three months, up to 36 months |
| Pain score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lili Ren, Ph.D | Contact | +86-755-22942466 | ren.lili@szhospital.com | |
| Min Zhang, Ph.D | Contact | +86-755-22942466 | zzuzhangmin@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Hui Qi, M.D | Shen Zhen People's Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shenzhen People's Hospital | Shenzhen | Guangdong | 518020 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| GnRHa combained with reverse addition therapy | Drug | Postoperative patients were treated with GnRHa combined with reverse addition treatment. |
|
|
A score of 0 means that you have never had this problem, and a score of 100 means that you are always troubled by this problem and feel unbearable. You can choose any number between 0 and 100 to represent your feelings. The higher the score, the worse your feelings will be.
| every three months, up to 36 months |
| The percent of pregnancy | The pregnancy will be meaured by B ultrasound. | 36 months |
| D000091662 | Genital Diseases |